Relapsed/Refractory Acute Myeloid Leukemia Pipeline

New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape

DelveInsight’s relapsed/refractory acute myeloid leukemia pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for relapsed/refractory acute myeloid leukemia treatment.

DelveInsight’s 'Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline relapsed/refractory acute myeloid leukemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the relapsed/refractory acute myeloid leukemia pipeline domain.

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

DelveInsight’s relapsed/refractory acute myeloid leukemia pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for relapsed/refractory acute myeloid leukemia treatment.
Leading relapsed/refractory acute myeloid leukemia companies such as Maxinovel Pty., Ltd., Cellectis S.A., Amgen, Ascentage Pharma, Shijiazhuang Yiling Pharmaceutical, CicloMed LLC, AB Science, Betta Pharmaceuticals Co., Ltd., Chongqing Precision Biotech Co., Ltd, Astellas Pharma, Keystone Nano, Cullinan Oncology, LLC, Arog Pharmaceuticals, Inc., GlycoMimetics Incorporated, Kite Pharma, Celyad Oncology SA, Novartis, PersonGen Biotherapeutics, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Mabwell (Shanghai) Bioscience Co., Ltd., Syndax Pharmaceuticals, Meryx, Inc., Cleave Therapeutics, Aptose Biosciences Inc., New Epsilon Innovation Limited, Guangdong Ruishun Biotech Co., Ltd, Hoffmann-La Roche, Prelude Therapeutics, Lava Therapeutics, Precigen, Inc, Celularity Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., JW Pharmaceutical, Eisai Inc., Wugen, Inc., Sumitomo Pharma Oncology, Inc., ADC Therapeutics S.A., ImmunoGen, Inc., Aptevo Therapeutics, Foghorn Therapeutics, TC Biopharm, Nanjing Sanhome Pharmaceutical, Co., Ltd., Nkarta Inc., Newave Pharmaceutical Inc, and others are evaluating new drugs for relapsed/refractory acute myeloid leukemia to improve the treatment landscape.
Emerging relapsed/refractory acute myeloid leukemia pipeline therapies in various stages of development include MAX-40279-01, UCART123v1.2, AMG 427, AMG 553, APG-2575, XY0206, Fosciclopirox, AB8939, MRX2843, CD123 CAR-T cells, ASP7517, Ceraxa, CLN-049, Crenolanib, Uproleselan, KITE-222, CYAD-02, VOB560, TAA05, MK-0482, ASTX660, 6MW3211, SNDX-5613, MRX-2843, CB-5339, CG-806, NEI-01, RC1012, RO7283420, IO-202, PRT1419, LAVA-051, PRGN-3006 T Cells, CYNK-001, SKLB1028, CWP232291, E7820, WU-NK-101, DSP-533, ADCT-301,I MGN632, APVO436, FHD-286, TCB008, SH1573, NKX101 - CAR NK cell therapy, LP-108, and others.
In August 2022, Foghorn® Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) had placed a full clinical hold on the Phase 1 dose escalation study of FHD-286, an inhibitor of BRG1/BRM, in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The dose escalation Phase 1 study of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol. The company plans to report data from the mUM study in the first half of 2023.
In May 2022, Aptose Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population. HM43239 received orphan drug designation from the FDA for the treatment of acute myeloid leukemia in 2018.
In April 2022, Precigen, Inc. announced that the FDA had granted Fast Track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) AML. PRGN-3006 was previously granted FDA Orphan Drug Designation.
In March 2022, Aptevo Therapeutics, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, had received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing a significant reduction in bone marrow blasts. This follows the Company's previous announcement that a patient receiving combination therapy is also moving to transplant after one cycle of therapy.
In December 2021, Notable Labs, Inc. initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia (AML) under the terms of a co-development agreement.
In December 2021, Astellas Pharma Inc. announced the presentation of new investigational data in acute myeloid leukemia (AML) and sickle cell disease at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition (December 11-14) in Atlanta, Ga.
In December 2021, Syndax Pharmaceuticals, Inc. announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company's highly selective oral menin inhibitor.
In June 2021, Cullinan Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared Cullinan Florentine’s IND application for CLN-049, a FLT3 x CD3 bispecific antibody for the treatment of relapsed/refractory acute myeloid leukemia (AML).

Request a sample and discover the recent advances in relapsed/refractory acute myeloid leukemia treatment drugs @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

The relapsed/refractory acute myeloid leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage relapsed/refractory acute myeloid leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the relapsed/refractory acute myeloid leukemia clinical trial landscape.

Relapsed/Refractory Acute Myeloid Leukemia Overview

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis that has a significant unmet medical need. Relapsed acute myeloid leukemia has a poor prognosis and is difficult to treat. The symptoms of acute myeloid leukemia are similar to those of other, less serious illnesses. Anemia symptoms include fatigue, weakness, shortness of breath during normal physical activities, lightheadedness, dizziness or faintness, headaches, and a pale complexion. Other general AML symptoms include loss of appetite, unexplained weight loss, bone or joint discomfort, fullness or swelling in the abdomen caused by an enlarged spleen or liver.

While relapsed/refractory AML is unlikely to be cured without allo-HCT, treatments are becoming less toxic, and remissions are lasting longer. Despite the increasing availability of novel agents, including targeted therapies, the management of acute myeloid leukemia relapse in adults remains a major therapeutic challenge.

$Relapsed-Refractory-Acute-Myeloid-Leukemia-Pipeline.jpg$

Find out more about relapsed/refractory acute myeloid leukemia treatment drugs @ Drugs for Relapsed/Refractory Acute Myeloid Leukemia Treatment

A snapshot of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
APG-2575	Ascentage Pharma	Phase I/II	Proto-oncogene protein c-bcl-2 inhibitor	Oral
Lanraplenib	Kronos Bio	Phase I/II	Syk kinase inhibitor	Oral
MAX-40279-01	Maxinovel Pharmaceuticals	Phase I/II	Fms-like tyrosine kinase 3 inhibitor	Subcutaneous
AB8939	AB Science	Phase I/II	Tubulin polymerisation inhibitor	Intravenous
Fosciclopirox	CicloMed	Phase I/II	Mitosis inhibitor	Intravenous
CLN 049	Cullian Oncology	Phase I	Fms-like tyrosine kinase 3 inhibitor	Parenteral

Learn more about the emerging relapsed/refractory acute myeloid leukemia pipeline therapies @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Assessment

The relapsed/refractory acute myeloid leukemia pipeline report proffers an integral view of the relapsed/refractory acute myeloid leukemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Ophthalmic, Intravenous, Oral, Subcutaneous, Topical, Parenteral, Transdermal
Therapeutics Assessment By Molecule Type: Oligonucleotide, Small molecule, Peptide
Therapeutics Assessment By Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors, Antibody-dependent cell cytotoxicity, CD3 antigen inhibitors, Fms-like tyrosine kinase 3 inhibitors, T lymphocyte stimulants, Syk kinase inhibitors, Fibroblast growth factor receptor antagonists, Fms-like tyrosine kinase 3 inhibitors, Apoptosis stimulants, Tubulin polymerisation inhibitors, Mitosis inhibitors
Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Maxinovel Pty., Ltd., Cellectis S.A., Amgen, Ascentage Pharma, Shijiazhuang Yiling Pharmaceutical, CicloMed LLC, AB Science, Betta Pharmaceuticals Co., Ltd., Chongqing Precision Biotech Co., Ltd, Astellas Pharma, Keystone Nano, Cullinan Oncology, LLC, Arog Pharmaceuticals, Inc., GlycoMimetics Incorporated, Kite Pharma, Celyad Oncology SA, Novartis, PersonGen Biotherapeutics, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Mabwell (Shanghai) Bioscience Co., Ltd., Syndax Pharmaceuticals, Meryx, Inc., Cleave Therapeutics, Aptose Biosciences Inc., New Epsilon Innovation Limited, Guangdong Ruishun Biotech Co., Ltd, Hoffmann-La Roche, Prelude Therapeutics, Lava Therapeutics, Precigen, Inc, Celularity Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., JW Pharmaceutical, Eisai Inc., Wugen, Inc., Sumitomo Pharma Oncology, Inc., ADC Therapeutics S.A., ImmunoGen, Inc., Aptevo Therapeutics, Foghorn Therapeutics, TC Biopharm, Nanjing Sanhome Pharmaceutical, Co., Ltd., Nkarta Inc., Newave Pharmaceutical Inc, and others.
Key Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapies: MAX-40279-01, UCART123v1.2, AMG 427, AMG 553, APG-2575, XY0206, Fosciclopirox, AB8939, MRX2843, CD123 CAR-T cells, ASP7517, Ceraxa, CLN-049, Crenolanib, Uproleselan, KITE-222, CYAD-02, VOB560, TAA05, MK-0482, ASTX660, 6MW3211, SNDX-5613, MRX-2843, CB-5339, CG-806, NEI-01, RC1012, RO7283420, IO-202, PRT1419, LAVA-051, PRGN-3006 T Cells, CYNK-001, SKLB1028, CWP232291, E7820, WU-NK-101, DSP-533, ADCT-301,I MGN632, APVO436, FHD-286, TCB008, SH1573, NKX101 - CAR NK cell therapy, LP-108, and others.

Dive deep into rich insights for new drugs for relapsed/refractory acute myeloid leukemia treatment, visit @ Relapsed/Refractory Acute Myeloid Leukemia Medications

Table of Contents

1.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report Introduction
2.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report Executive Summary
3.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Therapeutics
6.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline: Late Stage Products (Pre-registration)
7.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline: Late Stage Products (Phase III)
8.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline: Mid Stage Products (Phase II)
9.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline: Early Stage Products (Phase I)
10.	Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
11.	Inactive Products in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the relapsed/refractory acute myeloid leukemia pipeline therapeutics, reach out @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Drugs

Related Reports

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted relapsed/refractory acute myeloid leukemia epidemiology in the 7MM.

Acute Myeloid Leukemia Pipeline

Acute Myeloid Leukemia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Lymphocytic Leukemia Pipeline

Acute Lymphocytic Leukemia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.

Chronic Lymphocytic Leukemia Pipeline

Chronic Lymphocytic Leukemia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology, Octapharma, among others.

Chronic Myeloid Leukemia Pipeline

Chronic Myeloid Leukemia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others.

Other Trending Reports